Vivos Therapeutics Inc. (VVOS) shares plunged 26.1% on Thursday after the company announced a $4.3 million registered offering of 1.36 million shares. The offering, expected to close on September 20, will generate approximately $4.3 million in gross proceeds and will be used for working capital and general corporate purposes. This news follows a recent discussion on whether VVOS is a good stock to buy, with analysts focusing on the company’s capital allocation strategy, including dividend payouts and stock buyback programs.